Shots:
- J&J has reported positive topline Phase III (MajesTEC-9) results demonstrating that Tecvayli (teclistamab) monotx. significantly outperformed SoC in r/r multiple myeloma
- The study included patients with 1–3 prior therapies, all previously treated with anti-CD38 antibodies and lenalidomide. Most patients were refractory to anti-CD38 mAbs (85%), lenalidomide (79%), and their last therapy (>90%). Tecvayli achieved a 71% reduction in the risk of disease progression or death, and a 40% reduction in the risk of death vs PVd or Kd. This resulted in superior PFS and OS from the as early as 2L
- The bispecific T-cell engager had a clinically manageable safety profile consistent with prior data, with no new safety concerns, and the results were published in The NEJM
Ref: Johnson & Johnson| Image: Johnson & Johnson | Press Release
Related News: Johnson & Johnson Reports Topline P-IIb (JASMINE) Trial Data on Imaavy (Nipocalimab) for Systemic Lupus Erythematosus (SLE)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
